论文部分内容阅读
普伐他汀是一种胆固醇合成限速酶ＨＭＧ－ＣｏＡ还原酶的竞争性抑制剂，该研究旨在观察它对胆固醇结石病人血液及胆汁中脂类成分的影响。实验分为对照组２３例，实验组２０例，实验组病人术前每晚服用普伐他汀４０ｍｇ，连续一周，结果：实验组病人血液中胆固醇（ＣＨＤ）、甘油三酯（ＴＧ）、低密度脂蛋白（ＬＤＬ－Ｃ）明显下降（Ｐ＜０．０１），高密度脂蛋白（ＨＤＬ－Ｃ）升高（Ｐ＜０．０５），胆汁中胆固醇（ＣＨＤ）明显下降（Ｐ＜０．０１），磷脂（ＰＬ）降低（Ｐ＜０．０５）；胆汁酸（ＴＢＡ）无明显变化，胆固醇饱和指数（ＣＳＩ）无明显变化。结论：普伐他汀能有效地降低血液及胆汁中胆固醇含量，但同时也能降低胆汁中磷脂的含量，对胆汁中胆固醇饱和指数的影响不大。
Pravastatin is a competitive inhibitor of the rate-limiting enzyme for cholesterol synthesis, HMG-CoA reductase. The aim of this study was to investigate the effect of pravastatin on the lipid composition of blood and bile in cholesterol-lowering patients. The experimental group was divided into control group (n = 23) and experimental group (n = 20). Patients in the experimental group were treated with pravastatin 40 mg per night for one week before operation. The results showed that cholesterol, triglyceride (TG) (P <0.01), HDL-C (P <0.05), and cholesterol (CHD) in bile decreased significantly (P <0.01) ), Phospholipid (PL) decreased (P <0.05). There was no significant change of bile acid (TBA) and no significant change of cholesterol saturation index (CSI). CONCLUSION: Pravastatin can effectively reduce the cholesterol content in blood and bile, but it can also reduce the content of phospholipids in bile and has little effect on the cholesterol saturation index in bile.